Martin Misch

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Michael Platten, Lukas Bunse, Antje Wick et al. · Nature · 2021 · 425 citations · Full text

Medicine, Immunology, Oncology +17

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

Florian Ringel, Haiko Pape, Michael Sabel et al. · Neuro-Oncology · 2015 · 263 citations · Full text

Medicine, Oncology, Surgery +17

IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom

Florian Stockhammer, Martin Misch, Hans‐Joachim Helms et al. · Seizure · 2012 · 146 citations · Full text

Medicine, Neuroscience, Oncology +13

The genomic and transcriptional landscape of primary central nervous system lymphoma

Josefine Radke, Naveed Ishaque, Randi Koll et al. · Nature Communications · 2022 · 140 citations · Full text

Life Sciences, Molecular Biology, Oncology +17